Shares in Pulmatrix (NSDQ:PULM) jumped more than 8% today on rumors that the company’s collaboration partner Mylan (NSDQ:MYL) may be interested in a takeover bid. In 2015, the 2 companies inked an ex-U.S. development deal for PUR0200, Pulmatrix’s investigational bronchodilator for the treatment of chronic obstructive pulmonary disease. Mylan had an option on the rights […]
Pulmatrix Inc.
Pulmatrix shares droop on growing losses in FY2016 earnings report
Shares in Pulmatrix (NSDQ:PULM) fell today after the medical device maker posted earnings that showed losses growing while revenue shrunk compared with the prior year. The Lexington, Mass.-based company posted losses of $27.8 million, or $1.88 per share, on sales of $835,000 for the full year, with losses growing 6.4% while revenue shrunk 30.5% when compared […]
Pulmatrix updates on $3m offering
Pulmatrix (NSDQ:PULM) today updated pricing on an upcoming $3.3 million offering, looking to float 950,000 shares at $3.50 per share. The company said it expects to collect $3.1 million after paying for placement agent fees, which it calculated at $216,125. H.C. Wainwright & Co are acting as exclusive placement agents for the offering, according to an […]
Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general […]
Pulmatrix seeks to raise $5m in direct offering
Pulmatrix (NSDQ:PULM) said today that it landed an agreement with several institutional investors to purchase $5.0 million of shares of common stock in a registered direct offering. The Lexington, Mass.-based company agreed to sell 2 million shares of common stock at $2.50 apiece. The offering is expected to close on Feb. 2. Pulmatrix said it […]
Pulmatrix shares soar after winning FDA designation
Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystic fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. With the designation, the Lexington, Mass.-based company will receive 5 years of […]
Pulmatrix reports Q3 loss, revenue down 91%
Shares in Pulmatrix (NSDQ:PULM) remained steady after the biopharmaceutical company released its 3rd quarter results. The Lexington, Mass.-based company reeled in its losses by -35% to -$3.2 million compared to Q3 last year. Revenue fell -91% compared with the same period last year to $61,000 for the 3 months ended Sept. 30. Losses per share were -21¢. Pulmatrix cited the conclusion of […]
Pulmatrix lands $5.7 million grant from Uncle Sam
Pulmatrix Inc. landed a $5.7 million contract from the Defense Advanced Research Projects Agency to develop a drug/device combination aimed at protecting military personnel and civilians against biological weapons.
DARPA selected the Lexington, Mass.-based company as part of its “7-day Biodefense Initiative,” a project to develop inhaled therapeutics for respiratory infections caused by airborne agents.